The IκB kinase complex regulates the stability of cytokine-encoding mRNA induced by TLR-IL-1R by controlling degradation of regnase-1
Laboratory of Host Defense, World Premier International Immunology Frontier Research Center, Osaka University, Osaka, Japan. Nature Immunology
(Impact Factor: 20).
12/2011; 12(12):1167-75. DOI: 10.1038/ni.2137
Toll-like receptor (TLR) signaling activates the inhibitor of transcription factor NF-κB (IκB) kinase (IKK) complex, which governs NF-κB-mediated transcription during inflammation. The RNase regnase-1 serves a critical role in preventing autoimmunity by controlling the stability of mRNAs that encode cytokines. Here we show that the IKK complex controlled the stability of mRNA for interleukin 6 (IL-6) by phosphorylating regnase-1 in response to stimulation via the IL-1 receptor (IL-1R) or TLR. Phosphorylated regnase-1 underwent ubiquitination and degradation. Regnase-1 was reexpressed in IL-1R- or TLR-activated cells after a period of lower expression. Regnase-1 mRNA was negatively regulated by regnase-1 itself via a stem-loop region present in the regnase-1 3' untranslated region. Our data demonstrate that the IKK complex phosphorylates not only IκBα, thereby activating transcription, but also regnase-1, thereby releasing a 'brake' on IL-6 mRNA expression.
Figures in this publication
Available from: Osamu Takeuchi
- "Overexpression of Reg1 suppressed the luciferase activity in an RNase-activity dependent manner (Figure 1K). Consistent with a previous report (Iwasaki et al., 2011), overexpression of Reg1 suppressed Reg1 3′ UTR containing nucleotides 1-210, but not in the case where nucleotides 1-200, which contains the SL, were absent. Collectively, Reg1-bound mRNAs obtained by RIP-Seq are indeed targeted by Reg1 for degradation. "
[Show abstract] [Hide abstract]
ABSTRACT: Regnase-1 and Roquin are RNA binding proteins essential for degradation of inflammation-related mRNAs and maintenance of immune homeostasis. However, their mechanistic relationship has yet to be clarified. Here, we show that, although Regnase-1 and Roquin regulate an overlapping set of mRNAs via a common stem-loop structure, they function in distinct subcellular locations: ribosome/endoplasmic reticulum and processing-body/stress granules, respectively. Moreover, Regnase-1 specifically cleaves and degrades translationally active mRNAs and requires the helicase activity of UPF1, similar to the decay mechanisms of nonsense mRNAs. In contrast, Roquin controls translationally inactive mRNAs, independent of UPF1. Defects in both Regnase-1 and Roquin lead to large increases in their target mRNAs, although Regnase-1 tends to control the early phase of inflammation when mRNAs are more actively translated. Our findings reveal that differential regulation of mRNAs by Regnase-1 and Roquin depends on their translation status and enables elaborate control of inflammation.
Copyright © 2015 Elsevier Inc. All rights reserved.
Cell 05/2015; 161(5):1058-1073. DOI:10.1016/j.cell.2015.04.029 · 32.24 Impact Factor
Available from: Jiajia Xie
- "This complex signals to translocate the transcription factors, IRF7 and NF-jB, from the cytoplasm to the nucleus for subsequent production of IFN and inflammatory cytokines. Given that MyD88 recruits several proteins , such as IRAK4, IRAK1, IRF7, to form a large complex , MVP may also bind those proteins in a MyD88-mediated complex . Further studies are needed to verify these putative interactions. "
[Show abstract] [Hide abstract]
ABSTRACT: We previously demonstrated that major vault protein (MVP) is a novel virus-induced host factor and its expression upregulates type-I interferon production, leading to cellular antiviral response. However, it remains unclear whether the antiviral function of MVP is impaired during hepatitis B virus (HBV) infection and what mechanisms are involved. Therefore, the aim of this study was to assess whether HBV can alter expression of MVP despite the lack of type I IFN induction and shed light on the underlying mechanisms HBV utilizes to evade host innate immune response.
The ability of HBV S and E antigens inhibit MVP signaling in interferon induction pathways was evaluated by co-immunoprecipitation, immunofluorescence, quantitative RT-PCR, western blot and reporter assays.
In our current study, we found high levels of MVP in peripheral blood mononuclear cells, sera, and liver tissue from HBV-infected patients relative to healthy individuals. We determined that MVP intracellularly associates with MyD88, an adapter protein involved in virus-triggered induction of type-I IFN. Protein truncation analysis revealed that the middle domain of MVP (amino acid residues 310-620) was essential for MyD88 binding. Conversely, HBV inhibited MVP-induced type-I IFN production by suppressing MVP/MyD88 interaction. HBV antigens, both HBsAg and HBeAg, suppressed this interaction by competitively binding to the essential MyD88 binding region of MVP and limiting downstream IFN signaling.
MVP is a virus-induced protein capable of binding with MyD88 leading to type-I IFN production. HBV may evade an immune response by disrupting this interaction and limiting type-I IFN antiviral activity.
Copyright © 2014. Published by Elsevier B.V.
Journal of Hepatology 12/2014; 62(5). DOI:10.1016/j.jhep.2014.11.035 · 11.34 Impact Factor
- "Activation of IL-1R or TLR led to phosphorylation of regnase-1 via the inhibitor of transcription factor NF-jB (IjB) kinase (IKK) complex, thus inducing a rapid ubiquitin–proteasome-mediated degradation of the protein. This regn- ase-1 degradation was important for high IL-6 mRNA expression, and re-expression of regnase-1 after four hours, which itself is a NF-jB target gene, inhibited sustained IL-6 expression . Accordingly, Zc3h12a À/À mice show increased IL-6 production, and overexpressed regenase-1 interfered with the 3' UTR of the IL-6 mRNA and thereby accelerated IL-6 mRNA degradation . "
[Show abstract] [Hide abstract]
ABSTRACT: Interleukin-6 (IL-6) is a multifunctional cytokine with well-defined pro- and anti-inflammatory properties. Although only small amounts in the picogram range can be detected in healthy humans, IL-6 expression is highly and transiently up-regulated in nearly all pathophysiological states. IL-6 induces intracellular signaling pathways after binding to its membrane-bound receptor (IL-6R), which is only expressed on hepatocytes and certain subpopulations of leukocytes (classic signaling). Transduction of the signal is mediated by the membrane-bound β-receptor glycoprotein 130 (gp130). In a second pathway, named trans-signaling, IL-6 binds to soluble forms of the IL-6R (sIL-6R), and this agonistic IL-6/sIL-6R complexes can in principle activate all cells due to the uniform expression of gp130. Importantly, several soluble forms of gp130 (sgp130) are found in the human blood, which are considered to be the natural inhibitors of IL-6 trans-signaling. Most pro-inflammatory roles of IL-6 have been attributed to the trans-signaling pathway, whereas anti-inflammatory and regenerative signaling, including the anti-bacterial acute phase response of the liver, is mediated by IL-6 classic signaling. In this simplistic view, only a minority of cell types expresses the IL-6R and is therefore responsive for IL-6 classic signaling, whereas gp130 is ubiquitously expressed throughout the human body. However, several reports point towards a much more complex situation. A plethora of factors, including proteases, cytokines, chemical drugs, and intracellular signaling pathways, are able to modulate the cellular expression of the membrane-bound and soluble forms of IL-6R and gp130. In this review, we summarize current knowledge of regulatory mechanisms that control and regulate the dynamic expression of IL-6 and its two receptors.
Cytokine 06/2014; 70(1). DOI:10.1016/j.cyto.2014.05.024 · 2.66 Impact Factor
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.